In NK cells, disruption of endogenous CD38 has enabled the design of cell products which, when combined with anti-CD38 monoclonal antibodies (mAbs), confer anti-myeloma specificity for antibody-dependent cellular cytotoxicity (ADCC) while shielding NK cells from CD38-mediated fratricide (151). The gene discussed is CD38; the disease is plasma cell myeloma.